Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06254495 · ClinicalTrials.gov registry record · Phase 1

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

A Phase 1 study of Hodgkin Disease and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
57
Enrollment target
20
Study locations

NCT06254495: Active Phase 1 study of Hodgkin Disease and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT06254495 is a Phase 1 study of Hodgkin Disease and Lymphoma, Large B-Cell, Diffuse that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 57 participants, below the 275-participant average among 20 other Hodgkin Disease trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06254495, a Phase 1 study of Hodgkin Disease and Lymphoma, Large B-Cell, Diffuse, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
57 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Primary Outcome

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Conditions Studied

Hodgkin Disease Lymphoma, Large B-Cell, Diffuse Lymphoma, T-Cell, Peripheral Lymphoma, Large-Cell, Anaplastic

Interventions

  • DRUG PF-08046044/SGN-35C

Study Locations (20)

Kansas

  • The University of Kansas Cancer Center, Investigational Drug Services - Fairway
  • University of Kansas Clinical Research Center - Fairway
  • The University of Kansas Hospital Cambridge North Tower A - Kansas City
  • The University of Kansas Hospital - Kansas City
  • The University of Kansas Medical Center Medical Office Building - Kansas City
  • The University of Kansas Cancer Center - Overland Park - Overland Park
  • The University of Kansas Cancer Center - Indian Creek Campus - Overland Park
  • University of Kansas Cancer Center - Westwood

Florida

  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center - Coral Gables
  • University of Miami Hospital and Clinics - Deerfield Beach - Deerfield Beach
  • Sylvester Comprehensive Cancer Center - Hollywood - Hollywood
  • University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center - Miami
  • University Of Miami Hospitals And Clinics - Miami
  • Sylvester Comprehensive Cancer Center - Kendall - Miami

California

  • City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) - Duarte
  • IP Address: City of Hope Investigational Drug Services(IDS) - Duarte
  • University of California, San Francisco Medical Center - San Francisco

Nebraska

  • Nebraska Medicine - Bellevue Medical Center - Bellevue
  • Nebraska Medical Center - Omaha

Missouri

  • The University of Kansas Cancer Center - Lee's Summit - Lee's Summit

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2024-05-28
Est. Completion 2029-04-18
Phase Phase 1
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What the registry record for NCT06254495 still lists

NCT06254495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 275-participant average among 20 other Hodgkin Disease trials with a reported enrollment target (79% lower).

The record links to 4 conditions, with Hodgkin Disease appearing as the primary indexed condition, and to 1 intervention - of which PF-08046044/SGN-35C is the first listed.

NCT06254495 names 20 study sites across 5 states, led by Kansas, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06254495 about?

NCT06254495 is a clinical study titled "A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers". This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL...

What is the current status of trial NCT06254495?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2024-05-28. Estimated completion is 2029-04-18.

What conditions does trial NCT06254495 study?

This clinical trial studies the following conditions: Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic.

What interventions are being tested in trial NCT06254495?

The interventions under investigation include: PF-08046044/SGN-35C (DRUG).

Who is sponsoring clinical trial NCT06254495?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06254495 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06254495's enrollment target sits among peer trials

57 14th of 20 higher than 7 of 20 other Hodgkin Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hodgkin Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06254495, the US trial registry maintained by the National Library of Medicine. NCT06254495 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.